trending Market Intelligence /marketintelligence/en/news-insights/trending/aAxk-X84113gmU0F7ogXZw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Report: Johnson & Johnson fails to reverse $4.69B talc verdict

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Report: Johnson & Johnson fails to reverse $4.69B talc verdict

Johnson & Johnson has lost a motion to reverse a jury verdict from July ordering the company to pay $4.69 billion in damages to 22 women who claim its talc product contained asbestos that led to their ovarian cancer, Reuters reported.

Judge Rex Burlison of the 22nd Circuit Court in St. Louis denied Johnson & Johnson's request for an appeal, according to a Dec. 19 report from Reuters. Additional details of the ruling were not immediately available.

The total award in the verdict from July 12 comprised $550 million in compensatory damages, $25 million to each plaintiff and $4.14 billion in punitive damages. The litigation is among about 11,700 similar lawsuits faced by the world's largest healthcare company by market value. It has won several of those cases, and others have resulted in mistrials.

The New Brunswick, N.J.-based company was the subject of an investigation released Dec. 14 by Reuters alleging that the healthcare giant covered up its knowledge of carcinogens in its baby powder. The news outlet reported that Johnson & Johnson was aware of the impurity as early as the 1950s and eluded regulation from the U.S. Food and Drug Administration to market the powder despite the risks.

Amid fallout from the report, Johnson & Johnson repurchased $5 billion of its common stock after losing $25 billion in market value in one day.

The company called the report "one-sided, false and inflammatory" and has denied that the product is unsafe.